1. Joy MS, Hladik GA. Disorders of sodium water calcium and 
phosphorous homeostasis. In: Dipiro JT, Talbert RL, Yees CG, 
Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: 
A Pathophysiologic Approach. McGraw Hill, Medical 
Publishing Division. 2005. p. 937‑67.
2. Zenenberg RD, Carluccio AL, Merlin MA. Hyponatremia: 
Evaluation and management. Hosp Pract (1995) 2010;38:89‑96.
3. Hyponatremia: The Merck Manuals: The Merck Manual 
for Healthcare Professionals. Available from: http://www.
merckmanals.com/proessional/print/sec/12/ch156/ch156d.
html. [Last accessed on 2013 Aug 04].
4. Craig S, Schraga ED. Hyponatremia in emergency medicine. 
Medscape. Retrieved from: http://www.emedicine.medscape.
com/article/767624‑overview. [Last accessed on 2013 Jul 10].
5. Sterns RH, Nigwekar SU, Hix JK. The treatment of 
hyponatremia. Semin Nephrol 2009;29:282‑99.
6. Norenberg MD, Leslie KO, RobertsonAS. Association between 
rise in serum sodium and central pontine myelinolysis. Ann 
Neurol 1982;11:128‑35.
7. Kleinschmidt‑DeMastersBK, NorenbergMD. Rapid correction 
of hyponatremia causes demyelination: Relation to central 
pontine myelinolysis. Science 1981;211:1068‑70.
8. Helwig FC, Schutz CB, Kuhn HP. Water intoxication. 
Moribund patient cured by administration of hypertonic salt 
solution. J Am Med Assoc 1938;110:644‑5.
9. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, 
Sterns RH. Hyponatremia treatment guidelines 2007: Expert 
panel recommendations. Am J Med 2007;120:S1‑21.
10. Hyponatremia, Clinical Key; Elsevier. Retrieved from http://
www.clinicalkey.com/topics/nephrology/hyponatremia.html#
sectionTreatmentManagement. [Last accessed on 2013 Jul 10].
11. Thompson C, Hoorn EJ. Hyponatraemia: An overview of 
frequency, clinical presentation and complications. Best Pract 
Res Clin Endocrinol Metab 2012;26 Suppl 1:S1‑6.
12. Fenske W, Maier SK, BlechschmidtA, Allolio B, Störk S. Utility 
and limitations of the traditional diagnostic approach to 
hyponatremia: A diagnostic study. Am J Med 2010;123:652‑7.
13. Berl T, Quittnat‑Pelletier F, Verbalis JG, SchrierRW, Bichet DG, 
Ouyang J, et al. Oral tolvaptan is safe and effective in chronic 
hyponatremia. J Am Soc Nephrol 2010;21:705‑12.
14. Rose BD, Post TW. Clinical Physiology of Acid‑Base and 
Electrolyte Disorders. New York: McGraw‑Hill; 2001. p. 583‑8.
15. Wells BG, Dipiro JT, Schwinghammer TL, Dipiro CV. 
Electrolyte homeostasis. Pharmacotherapy Handbook. The 
McGraw‑Hill Companies, Inc; 2009. p. 881‑96.
16. Reilly T, Chavez B. Tolvaptan (Samsca) for hyponatremia: Is 
it a worth salt? Pharm Ther 2009;34:543‑7.
17. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, 
Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin 
V2‑receptor antagonist, for hyponatremia. N Engl J Med 
2006;355:2099‑112.
18. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS, 
et al. Efficacy and safety of oral tolvaptan therapy in patients 
with the syndrome of inappropriate antidiuretic hormone 
secretion. Eur J Endocrinol 2011;164:725‑32.